These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3534002)

  • 1. Prevention of lethal murine graft versus host disease by treatment of donor cells with L-leucyl-L-leucine methyl ester.
    Charley M; Thiele DL; Bennett M; Lipsky PE
    J Clin Invest; 1986 Nov; 78(5):1415-20. PubMed ID: 3534002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lethal graft-vs-host disease across major histocompatibility barriers: requirement for leucyl-leucine methyl ester sensitive cytotoxic T cells.
    Thiele DL; Charley MR; Calomeni JA; Lipsky PE
    J Immunol; 1987 Jan; 138(1):51-7. PubMed ID: 2946780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment of murine donor grafts with L-leucyl-L-leucine methyl ester: elimination of graft-versus-host disease without detrimental effects on engraftment.
    Blazar BR; Thiele DL; Vallera DA
    Blood; 1990 Feb; 75(3):798-805. PubMed ID: 1967541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal graft-versus-host disease is initiated by donor T cells distinct from classic cytotoxic T lymphocytes.
    Thiele DL; Eigenbrodt ML; Bryde SE; Eigenbrodt EH; Lipsky PE
    J Clin Invest; 1989 Dec; 84(6):1947-56. PubMed ID: 2531761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leucyl-leucine methyl ester treatment of donor cells permits establishment of immunocompetent parent----F1 chimeras that are selectively tolerant of host alloantigens.
    Thiele DL; Calomeni JA; Lipsky PE
    J Immunol; 1987 Oct; 139(7):2137-42. PubMed ID: 3309052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lethal graft-vs-host disease induced by a class II MHC antigen only disparity is not mediated by cytotoxic T cells.
    Thiele DL; Bryde SE; Lipsky PE
    J Immunol; 1988 Nov; 141(10):3377-82. PubMed ID: 3053897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk.
    Hsieh MH; Varadi G; Flomenberg N; Korngold R
    Biol Blood Marrow Transplant; 2002; 8(6):303-15. PubMed ID: 12108916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of leucyl-leucine methyl ester-sensitive cytotoxic cells in skin allograft rejection.
    Thiele DL; Geissler GH; Williams FH; Lipsky PE
    Transplantation; 1992 Jun; 53(6):1334-40. PubMed ID: 1604489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of the use of L-leucyl-L-leucine methyl ester in canine allogeneic marrow transplantation.
    Raff RF; Severns EM; Storb R; Graham TC; Sale G; Schuening FG; Appelbaum FR
    Transplantation; 1993 Jun; 55(6):1244-9. PubMed ID: 8516809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ex vivo treatment of murine splenocyte-supplemented bone marrow inocula with mafosfamide prior to allogeneic transplantation in an attempt to prevent lethal graft-versus-host disease without compromising engraftment.
    Kohn FR; Sladek NE
    Immunopharmacol Immunotoxicol; 1988; 10(3):387-98. PubMed ID: 3058776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
    Zhao J; Zhao XY; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2497-502. PubMed ID: 16321278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete allogeneic hematopoietic chimerism achieved by in utero hematopoietic cell transplantation and cotransplantation of LLME-treated, MHC-sensitized donor lymphocytes.
    Hayashi S; Hsieh M; Peranteau WH; Ashizuka S; Flake AW
    Exp Hematol; 2004 Mar; 32(3):290-9. PubMed ID: 15003315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of donor lymphocytes on the incidence of primary graft failure after allogeneic bone marrow transplantation in a murine model.
    Uharek L; Glass B; Gaska T; Gassmann W; Loeffler H; Mueller-Ruchholtz W
    Br J Haematol; 1994 Sep; 88(1):79-87. PubMed ID: 7803260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of acute graft-vs-host disease by a single low-dose cyclophosphamide injection following allogeneic bone marrow transplantation.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2008 Dec; 36(12):1750-9. PubMed ID: 18809241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
    Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA
    J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.